Drugs / Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes
Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05989828 | Dec 2024 → Dec 2027 expected | triple-negative breast carcinoma | University of Southern California | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05989828 ↗ |
| Action | Deplete | “these A2-ESO-1 TCR-T cells find and attack tumor cells that express NY-ESO-1.” NCT05989828 ↗ |
| Modality | Cell therapy | “The A2-ESO-1 TCR-T cells are T cells that have been removed from the patient's blood through a process called leukapheresis and then changed in the laboratory to recognize...” NCT05989828 ↗ |
| Route | Intravenous | “A2-ESO-1 TCR-T cells IV over 30 minutes on day 0” NCT05989828 ↗ |